Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether 8 weeks treatment with mometasone furoate nasal spray (MFNS), twice daily, is safe and effective in treating adenoid hypertrophy in children.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mometasone Furoate nasal spray | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mometasone Furoate nasal spray | Drug | Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Adenoid/Choana (A/C) Index Grade | Changes in adenoid size were assessed by nasopharyngoscopic examination and were determined using the Adenoid/Choana (A/C) Index. Grades were assigned to intervals of A/C ratio percentages: grade I (0-25%), II (26-50%), III (51-75%) and IV (76-100%). Changes in adenoid size were expressed as the mean difference between grades at baseline and study visit. Positive values indicated a decrease in adenoid size, a 0 value indicated that size remained the same, and negative values indicated an increase in adenoid size. | Baseline (visit 2), Weeks 4 (visit 3), Week 8 (visit 4) |
| Measure | Description | Time Frame |
|---|---|---|
| Total Severity Symptom Scores: Morning and Evening (AM & PM) | Symptoms were assessed by whole-number linear scale to grade their severity. Scores were recorded AM & PM (a difference of 12 hours) & were based on severity within 12 hours of prior recording. The following symptoms were evaluated: Snoring; Nasal obstruction & discharge; Breathing difficulty; Oral respiration; Ear pain. Severity was graded according to the following scale: 0=absent; 1=mild; 2=moderate; 3=severe. Severity was scored individually and summed to obtain the Total Symptom Severity Score. The maximum total score possible was 36 daily; 18 for both AM (6 symptoms times max severity of 3)and PM. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
135 participants were screened, a total of 132 participants were randomized to receive either Mometasone furoate nasal spray (MFNS) (n=66) or placebo nasal spray (n=66).
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Mometasone Furoate Nasal Spray | 1 spray (50 mcg) in each nostril twice daily (equivalent to 200 mcg per day) administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| FG001 | Placebo Nasal Spray | 1 spray in each nostril twice daily administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Mometasone Furoate Nasal Spray | 1 spray (50 mcg) in each nostril twice daily (equivalent to 200 mcg per day) administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| BG001 | Placebo Nasal Spray |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Adenoid/Choana (A/C) Index Grade | Changes in adenoid size were assessed by nasopharyngoscopic examination and were determined using the Adenoid/Choana (A/C) Index. Grades were assigned to intervals of A/C ratio percentages: grade I (0-25%), II (26-50%), III (51-75%) and IV (76-100%). Changes in adenoid size were expressed as the mean difference between grades at baseline and study visit. Positive values indicated a decrease in adenoid size, a 0 value indicated that size remained the same, and negative values indicated an increase in adenoid size. | A total of 132 participants were included in the intent-to-treat (ITT) population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data are summarized in terms of the number of participants providing data at the relevant time point. | Posted | Mean | Standard Deviation | Score on a Scale | Baseline (visit 2), Weeks 4 (visit 3), Week 8 (visit 4) |
|
Up to Week 24
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Mometasone Furoate Nasal Spray | 1 spray (50 mcg) in each nostril twice daily (equivalent to 200 mcg per day) administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Appendicitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pyrexia | General disorders | MedDRA (13.0) | Systematic Assessment |
The results of this study as presented are drawn from the clinical study report and should be reviewed with caution as there were inaccuracies in the database resulting from medication errors in some participants.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp | ClinicalTrialsDisclosure@merck.com |
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
|
| Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Total Frequency Symptom Scores: AM & PM | Symptoms were assessed by whole-number linear scale to grade their frequency. Scores were recorded AM & PM (a difference of 12 hours) & were based on frequency within 12 hours of prior recording. The following signs/symptoms were evaluated: Snoring; Nasal obstruction; and nasal discharge; Breathing difficulty; Oral respiration; Ear pain. Frequency was graded according to the following scale: 0=absent; 1=intermittent; 2=persistent. The frequency of symptoms was scored individually and summed to obtain the Total Frequency Symptom Score. The maximum total score possible was 24 daily; 12 for both AM (6 symptoms times max frequency of 2) and PM. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Bilateral Tympanogram Results of: Normal, Abnormal, or Not Done | Tympanometry was performed in children ages 2-11 by certified audiologists. Results were categorized based on audiologist's assessment as either being normal (normal pressure in the middle ear with normal mobility of the eardrum and the conduction bones) , abnormal (abnormal pressure in the middle ear and/or abnormal mobility of the eardrum and the conduction bones), or tympanometry was not done (evaluation not completed). Results were assessed at baseline, Week 4 (Visit 3), and endpoint Week 8 (end of treatment). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Otoscopic Results of: Normal or Abnormal | Otoscopic examination was performed of the right and left ear canals at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on audiologist's assessment as either being normal (ear canal structures appear normal) or abnormal (ear canal structures appear abnormal). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Rhinoscopic- Septum Results of: Aligned, Non-Obstructive, or Obstructive Deviation | Rhinoscopic examination of the septum was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment as either being aligned (septum is aligned), non-obstructive (septum is not aligned but the deviation is non-obstructive), or obstructive (septum is deviated and obstructive) deviation. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Rhinoscopic-Inferior Turbinates Results of: Normal, Hypertrophic, and Hypotrophic | Rhinoscopic examination of the inferior turbinates was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment as either being normal appearance (normal size) , hypertrophic (swollen/normal size increased), or hypotrophic (normal size diminished). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Rhinoscopic- Middle Meatus Results of: Patent, Partial Obstruction or Total Obstruction | Rhinoscopic examination of the middle meatus was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment into 3 categories: patent (easily observed), partial obstruction (partially blocked from view), or total obstruction (completely blocked from view). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Rhinomanometry Results- Left and Right Nasal Fossa: Inspiratory Resistance | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. These findings were used to calculate inspiratory nasal airway resistance reported in Pascal/centimeter^3/second (Pa/cm^3/sec). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Rhinomanometry Results- Left and Right Nasal Fossa: Expiratory Resistance | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. These findings were used to calculate expiratory nasal airway resistance reported in Pascal/centimeter^3/second (Pa/cm^3/sec). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Rhinomanometry Results- Left and Right Nasal Fossa: Inspiration Flow at 75 Pa | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. Inspiration flow was calculated at 75 Pa. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Rhinomanometry Results- Left and Right Nasal Fossa: Expiratory Flow at 75 Pa | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. Expiratory flow was calculated at 75 Pa. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Pure-Tone Audiometric Results of: Normal, Abnormal, or Not Done | Pure-tone audiometry was performed in children ages 7-11 by certified audiologists. Results were categorized based on audiologist's assessment as either being normal (within normal limits), abnormal (outside normal limits), or audiometry was not done (not performed). Results were assessed at baseline, Week 4 (Visit 3), and endpoint Week 8 (end of treatment). | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Acoustic Rhinometry Results- Minimal Cross-Sectional Area: Left and Right Nasal Fossa | Acoustic rhinometry examination of the left & right Nasal Fossa was performed by principal investigators at baseline & each visit throughout treatment in participants ages 7-11 years. Acoustic rhinometry is a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. The technique is based on an analysis of sound waves reflected from the nasal cavities. Measurements were taken for each side of the nose (nasopharyngeal minimum cross-sectional area) & were reported in cm^3. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Acoustic Rhinometry Results- Nasopharyngeal Volume (NPV): Left and Right Nasal Fossa | Acoustic rhinometry examination of the left & right Nasal Fossa was performed by principal investigators at baseline & each visit throughout treatment in participants ages 7-11 years. Acoustic rhinometry is a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. The technique is based on an analysis of sound waves reflected from the nasal cavities. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Number of Participants With Pediatric Sleep Questionnaire (PSQ)- Impact on Health-Related Quality of Life (HRQL) Results of: Mild, Moderate, or Severe | PSQ consists of 90 variables divided into 3 different factors:snoring, somnolence, and behavior. All positive Snoring and Somnolence answers scored with Yes=1 and No=0, and scores averaged to obtain a total score between 0.00 and 1.00. Behavior factor scored between 1-3, and scores averaged for total score of 1 to 3. Increased scores indicate increasing abnormality of sleep. Based on determined cut-offs, participants were categorized as having mild, moderate, or severe discomfort due to interference of sleep. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Quality of Life Questionnaire (PedsQL) Total Score (Ages 2-4) | The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. This modular instrument consists of 21 items using a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Quality of Life Questionnaire (PedsQL) Total Score (Ages 5-7) | The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. Questionnaire consists of 23 items using a 3-point scale: from 0 (not at all), 2 (sometimes), 4 (a lot). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Quality of Life Questionnaire (PedsQL) Total Score (Ages 8-12) | The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. This modular instrument consists of 23 items using a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL. | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Obstructive Sleep Apnea-18 (OSA-18) Questionnaire Total Score | 18 items of the survey were graded on a 7-point ordinal scale. Caregivers were asked to describe how often in the last 4 weeks had the child exhibited specific symptoms according to the following scale: 1: none of the time; 2: hardly any of the time; 3: a little of the time; 4: some of the time; 5: a good bit of the time; 6: most of the time; 7: all of the time. All scores were summed (total score: 18-126). Grading was as follows:
| Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
| Lost to Follow-up |
|
1 spray in each nostril twice daily administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Mometasone Furoate Nasal Spray (MFNS) |
1 spray (50 mcg) in each nostril twice daily (equivalent to 200 mcg per day) administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
| OG001 | Placebo Nasal Spray | 1 spray in each nostril twice daily administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). |
|
|
| Secondary | Total Severity Symptom Scores: Morning and Evening (AM & PM) | Symptoms were assessed by whole-number linear scale to grade their severity. Scores were recorded AM & PM (a difference of 12 hours) & were based on severity within 12 hours of prior recording. The following symptoms were evaluated: Snoring; Nasal obstruction & discharge; Breathing difficulty; Oral respiration; Ear pain. Severity was graded according to the following scale: 0=absent; 1=mild; 2=moderate; 3=severe. Severity was scored individually and summed to obtain the Total Symptom Severity Score. The maximum total score possible was 36 daily; 18 for both AM (6 symptoms times max severity of 3)and PM. | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Mean | Standard Deviation | Score on a scale | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Total Frequency Symptom Scores: AM & PM | Symptoms were assessed by whole-number linear scale to grade their frequency. Scores were recorded AM & PM (a difference of 12 hours) & were based on frequency within 12 hours of prior recording. The following signs/symptoms were evaluated: Snoring; Nasal obstruction; and nasal discharge; Breathing difficulty; Oral respiration; Ear pain. Frequency was graded according to the following scale: 0=absent; 1=intermittent; 2=persistent. The frequency of symptoms was scored individually and summed to obtain the Total Frequency Symptom Score. The maximum total score possible was 24 daily; 12 for both AM (6 symptoms times max frequency of 2) and PM. | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Mean | Standard Deviation | Score on a scale | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Bilateral Tympanogram Results of: Normal, Abnormal, or Not Done | Tympanometry was performed in children ages 2-11 by certified audiologists. Results were categorized based on audiologist's assessment as either being normal (normal pressure in the middle ear with normal mobility of the eardrum and the conduction bones) , abnormal (abnormal pressure in the middle ear and/or abnormal mobility of the eardrum and the conduction bones), or tympanometry was not done (evaluation not completed). Results were assessed at baseline, Week 4 (Visit 3), and endpoint Week 8 (end of treatment). | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Otoscopic Results of: Normal or Abnormal | Otoscopic examination was performed of the right and left ear canals at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on audiologist's assessment as either being normal (ear canal structures appear normal) or abnormal (ear canal structures appear abnormal). | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Rhinoscopic- Septum Results of: Aligned, Non-Obstructive, or Obstructive Deviation | Rhinoscopic examination of the septum was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment as either being aligned (septum is aligned), non-obstructive (septum is not aligned but the deviation is non-obstructive), or obstructive (septum is deviated and obstructive) deviation. | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Rhinoscopic-Inferior Turbinates Results of: Normal, Hypertrophic, and Hypotrophic | Rhinoscopic examination of the inferior turbinates was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment as either being normal appearance (normal size) , hypertrophic (swollen/normal size increased), or hypotrophic (normal size diminished). | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Rhinoscopic- Middle Meatus Results of: Patent, Partial Obstruction or Total Obstruction | Rhinoscopic examination of the middle meatus was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment into 3 categories: patent (easily observed), partial obstruction (partially blocked from view), or total obstruction (completely blocked from view). | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Rhinomanometry Results- Left and Right Nasal Fossa: Inspiratory Resistance | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. These findings were used to calculate inspiratory nasal airway resistance reported in Pascal/centimeter^3/second (Pa/cm^3/sec). | This analysis was only performed in a cohort of the ITT in participants aged 7-11 years old (MFSN=19, Placebo=20). | Posted | Mean | Standard Deviation | Pa/cm^3/sec | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Rhinomanometry Results- Left and Right Nasal Fossa: Expiratory Resistance | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. These findings were used to calculate expiratory nasal airway resistance reported in Pascal/centimeter^3/second (Pa/cm^3/sec). | This analysis was only performed in a cohort of the ITT in participants ages 7-11 years old (MFSN=19, Placebo=20). | Posted | Mean | Standard Deviation | Pa/cm^3/sec | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Rhinomanometry Results- Left and Right Nasal Fossa: Inspiration Flow at 75 Pa | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. Inspiration flow was calculated at 75 Pa. | This analysis was only performed in a cohort of the ITT in participants ages 7-11 years old (MFSN=19, Placebo=20). | Posted | Mean | Standard Deviation | cm^3/sec | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Rhinomanometry Results- Left and Right Nasal Fossa: Expiratory Flow at 75 Pa | Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years. Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. Expiratory flow was calculated at 75 Pa. | This analysis was only performed in a cohort of the ITT in participants ages 7-11 years old (MFSN=19, Placebo=20). | Posted | Mean | Standard Deviation | cm^3/sec | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Pure-Tone Audiometric Results of: Normal, Abnormal, or Not Done | Pure-tone audiometry was performed in children ages 7-11 by certified audiologists. Results were categorized based on audiologist's assessment as either being normal (within normal limits), abnormal (outside normal limits), or audiometry was not done (not performed). Results were assessed at baseline, Week 4 (Visit 3), and endpoint Week 8 (end of treatment). | This analysis was only performed in a cohort of the ITT in participants ages 7-11 years old (MFSN=19, Placebo=20). | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Acoustic Rhinometry Results- Minimal Cross-Sectional Area: Left and Right Nasal Fossa | Acoustic rhinometry examination of the left & right Nasal Fossa was performed by principal investigators at baseline & each visit throughout treatment in participants ages 7-11 years. Acoustic rhinometry is a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. The technique is based on an analysis of sound waves reflected from the nasal cavities. Measurements were taken for each side of the nose (nasopharyngeal minimum cross-sectional area) & were reported in cm^3. | This analysis was only performed in a cohort of the ITT in participants ages 7-11 years old (MFSN=19, Placebo=20). | Posted | Mean | Standard Deviation | cm^3 | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Acoustic Rhinometry Results- Nasopharyngeal Volume (NPV): Left and Right Nasal Fossa | Acoustic rhinometry examination of the left & right Nasal Fossa was performed by principal investigators at baseline & each visit throughout treatment in participants ages 7-11 years. Acoustic rhinometry is a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. The technique is based on an analysis of sound waves reflected from the nasal cavities. | This analysis was only performed in a cohort of the ITT in participants ages 7-11 years old (MFSN=19, Placebo=20). | Posted | Mean | Standard Deviation | cm^3 | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Number of Participants With Pediatric Sleep Questionnaire (PSQ)- Impact on Health-Related Quality of Life (HRQL) Results of: Mild, Moderate, or Severe | PSQ consists of 90 variables divided into 3 different factors:snoring, somnolence, and behavior. All positive Snoring and Somnolence answers scored with Yes=1 and No=0, and scores averaged to obtain a total score between 0.00 and 1.00. Behavior factor scored between 1-3, and scores averaged for total score of 1 to 3. Increased scores indicate increasing abnormality of sleep. Based on determined cut-offs, participants were categorized as having mild, moderate, or severe discomfort due to interference of sleep. | A total of 132 participants were included in the ITT population. The ITT population included all randomized participants who received at least one dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. | Posted | Number | Participants | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Quality of Life Questionnaire (PedsQL) Total Score (Ages 2-4) | The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. This modular instrument consists of 21 items using a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL. | The ITT population included all randomized participants who received >= 1 dose after commencement of treatment. At baseline (visit 2), 52 randomized participants were between 2 and 4 years old, 23 participants in MFNS & 29 participants in Placebo group. Questionnaire was answered in accordance with the actual age of each participant at each visit. | Posted | Mean | Standard Deviation | Score on a scale | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Quality of Life Questionnaire (PedsQL) Total Score (Ages 5-7) | The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. Questionnaire consists of 23 items using a 3-point scale: from 0 (not at all), 2 (sometimes), 4 (a lot). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL. | The ITT population included all randomized participants who received >= 1 dose after commencement of treatment. At baseline (visit 2), 52 randomized participants were between 5 and 7 years old, 28 participants in MFNS & 24 subjects in Placebo group. Questionnaire was answered in accordance with the actual age of each participant at each visit. | Posted | Mean | Standard Deviation | Score on a scale | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Quality of Life Questionnaire (PedsQL) Total Score (Ages 8-12) | The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. This modular instrument consists of 23 items using a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL. | The ITT population included all randomized participants who received >= 1 dose after commencement of treatment. At baseline (visit 2), 28 randomized participants were between 8-12 years old, 15 participants in MFNS & 13 participants in Placebo group. Questionnaire was answered in accordance with the actual age of each participant at each visit. | Posted | Mean | Standard Deviation | Score on a scale | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| Secondary | Obstructive Sleep Apnea-18 (OSA-18) Questionnaire Total Score | 18 items of the survey were graded on a 7-point ordinal scale. Caregivers were asked to describe how often in the last 4 weeks had the child exhibited specific symptoms according to the following scale: 1: none of the time; 2: hardly any of the time; 3: a little of the time; 4: some of the time; 5: a good bit of the time; 6: most of the time; 7: all of the time. All scores were summed (total score: 18-126). Grading was as follows:
| A total of 132 subjects were included in the ITT population. The ITT population included all randomized participants who received >=1 dose after commencement of treatment. Data summarized in terms of the number of participants providing data at the relevant time point. 1 participant in Placebo group did not answer this questionnaire at baseline. | Posted | Mean | Standard Deviation | Score on a scale | Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) |
|
|
|
| 2 |
| 66 |
| 18 |
| 66 |
| EG001 | Placebo Nasal Spray | 1 spray in each nostril twice daily administered for 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months). | 3 | 66 | 17 | 66 |
| Orchitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Oropharyngeal Pain | Respiratory, thoracic and mediastinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Pharyngotonsillitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Sinusitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA (13.0) | Systematic Assessment |
|
The Principal Investigator agrees not to publish or publicly present any interim results of the Study without prior written consent of the SPONSOR. The Principal Investigator further agrees to provide thirty (30) days written notice to the SPONSOR prior to submission for publication or presentation to permit the SPONSOR to review copies of abstracts or manuscripts for publication which report any results of the Study.
| Visit 4 AM (n=62 MFNS, n=60 Placebo) |
|
| Visit 2 PM (n=66 MFNS, n=66 Placebo) |
|
| Visit 3 PM (n=64 MFNS, n=65 Placebo) |
|
| Visit 4 PM (n=62 MFNS, n=60 Placebo) |
|
| Visit 4 AM (n=62 MFNS, n=60 Placebo) |
|
| Visit 2 PM (n=66 MFNS, n=66 Placebo) |
|
| Visit 3 PM (n=64 MFNS, n=65 Placebo) |
|
| Visit 4 PM (n=62 MFNS, n=60 Placebo) |
|
| Visit 2- Not Done (n=66 MFNS, n=66 Placebo) |
|
| Visit 3- Normal (n=65 MFNS, n=65 Placebo) |
|
| Visit 3- Abnormal (n=65 MFNS, n=65 Placebo) |
|
| Visit 3- Not Done (n=65 MFNS, n=65 Placebo) |
|
| Visit 4- Normal (n=62 MFNS, n=60 Placebo) |
|
| Visit 4- Abnormal (n=62 MFNS, n=60 Placebo) |
|
| Visit 4- Not Done (n=62 MFNS, n=60 Placebo) |
|
| Right Otoscopy Visit 3- Normal (n=65, n=65) |
|
| Right Otoscopy Visit 3- Abnormal (n=65, n=65) |
|
| Right Otoscopy Visit 4- Normal (n=62, n=60) |
|
| Right Otoscopy Visit 4- Abnormal (n=62, n=60) |
|
| Left Otoscopy: Visit 2- Normal (n=66, n=66) |
|
| Left Otoscopy: Visit 2- Abnormal (n=66, n=66) |
|
| Left Otoscopy Visit 3- Normal (n=65, n=65) |
|
| Left Otoscopy Visit 3- Abnormal (n=65, n=65) |
|
| Left Otoscopy Visit 4- Normal (n=62, n=60) |
|
| Left Otoscopy Visit 4- Abnormal (n=62, n=60) |
|
| Vist 2 Obstructive Deviation (n=66, n=66) |
|
| Visit 3 Aligned (n=65, n=65) |
|
| Visit 3 Non-obstructive Deviation (n=65, n=65) |
|
| Visit 3 Obstructive Deviation (n=65, n=65) |
|
| Visit 4 Aligned (n=62, n=60) |
|
| Visit 4 Non-obstructive Deviation (n=62, n=60) |
|
| Visit 4 -Obstructive Deviation (n=62, n=60) |
|
| Vist 2 Hypotrophic (n=66, n=66) |
|
| Visit 3 Normal Appearance (n=65, n=65) |
|
| Visit 3 Hypertrophic (n=65, n=65) |
|
| Visit 3 Hypotrophic (n=65, n=65) |
|
| Visit 4 Normal Appearance (n=62, n=60) |
|
| Visit 4 Hypertrophic (n=62, n=60) |
|
| Visit 4 Hypotrophic (n=62, n=60) |
|
| Visit 2- Total Obstruction (n=66, n=66) |
|
| Visit 3- Patent (n=65, n=65) |
|
| Visit 3- Partial Obstruction (n=65, n=65) |
|
| Visit 3- Total Obstruction (n=65, n=65) |
|
| Visit 4- Patent (n=62, n=60) |
|
| Visit 4- Partial Obstruction (n= 62, n=60) |
|
| Visit 4- Total Obstruction (n=62, n=60) |
|
| Visit 4- Left Nasal Fossa (n=19, n=19) |
|
| Visit 2- Right Nasal Fossa (n=19, n=20) |
|
| Visit 3- Right Nasal Fossa (n=18, n=18) |
|
| Visit 4- Right Nasal Fossa (n=19, n=19) |
|
| Visit 4- Left Nasal Fossa (n=19, n=19) |
|
| Visit 2- Right Nasal Fossa (n=19, n=20) |
|
| Visit 3- Right Nasal Fossa (n=18, n=18) |
|
| Visit 4- Right Nasal Fossa (n=19, n=19) |
|
| Visit 4- Left Nasal Fossa (n=19, n=19) |
|
| Visit 2- Right Nasal Fossa (n=19, n=20) |
|
| Visit 3- Right Nasal Fossa (n=18, n=18) |
|
| Visit 4- Right Nasal Fossa (n=19, n=19) |
|
| Visit 4- Left Nasal Fossa (n=19, n=19) |
|
| Visit 2- Right Nasal Fossa (n=19, n=20) |
|
| Visit 3- Right Nasal Fossa (n=18, n=18) |
|
| Visit 4- Right Nasal Fossa (n=19, n=19) |
|
| Visit 2- Not Done (n=19 MFNS, n= 21 Placebo) |
|
| Visit 3- Normal (n=20 MFNS, n=21 Placebo) |
|
| Visit 3- Abnormal (n=20 MFNS, n=21 Placebo) |
|
| Visit 3- Not Done (n=20 MFNS, n=21 Placebo) |
|
| Visit 4- Normal (n=19 MFNS, n=20 Placebo) |
|
| Visit 4- Abnormal (n=19 MFNS, n=20 Placebo) |
|
| Visit 4- Not Done (n=19 MFNS, n=20 Placebo) |
|
| Visit 4- Left Nasal Fossa (n=19, n=19) |
|
| Visit 2- Right Nasal Fossa (n=19, n=20) |
|
| Visit 3- Right Nasal Fossa (n=18, n=18) |
|
| Visit 4- Right Nasal Fossa (n=19, n=19) |
|
| Visit 4- Left Nasal Fossa (n=19, n=19) |
|
| Visit 2- Right Nasal Fossa (n=19, n=20) |
|
| Visit 3- Right Nasal Fossa (n=19, n=18) |
|
| Visit 4- Right Nasal Fossa (n=19, n=19) |
|
| Visit 2- Severe (n=66 MFNS, n=65 Placebo) |
|
| Visit 3- Mild (n=65 MFNS, n=65 Placebo) |
|
| Visit 3- Moderate (n=65 MFNS, n=Placebo) |
|
| Visit 3- Severe (n=65 MFNS, n=65 Placebo) |
|
| Visit 4- Mild (n=62 MFNS, n=59 Placebo) |
|
| Visit 4- Moderate (n=62 MFNS, n=59 Placebo) |
|
| Visit 4- Severe (n=62 MFNS, n= 59 Placebo) |
|
| Visit 4 (n=18 MFNS, n=25 Placebo) |
|
| Visit 4 (n=28 MFNS, n=22 Placebo) |
|
| Visit 4 (n=15 MFNS, n=13 Placebo) |
|
| Visit 4 (n=62 MFNS, n= 59 Placebo) |
|